$3.22
1.26% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
IE000LK2BOB4
Symbol
MURA
Sector
Industry

Mural Oncology Stock price

$3.22
-0.82 20.30% 1M
+0.15 4.89% 6M
-2.70 45.61% YTD
-2.33 41.98% 1Y
-0.58 15.26% 3Y
-0.58 15.26% 5Y
-0.58 15.26% 10Y
NYSE, Closing price Fri, Dec 27 2024
+0.04 1.26%
ISIN
IE000LK2BOB4
Symbol
MURA
Sector
Industry

Key metrics

Market capitalization $54.93m
Enterprise Value $-111.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.79
P/B ratio (TTM) P/B ratio 0.32
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-160.92m
Free Cash Flow (TTM) Free Cash Flow $-140.75m
Cash position $175.50m
EPS (TTM) EPS $-9.14
P/E forward negative
Short interest 2.42%
Show more

Is Mural Oncology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mural Oncology Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Mural Oncology forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Mural Oncology forecast:

Buy
100%

Financial data from Mural Oncology

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.26 3.26
-
-
-3.26 -3.26
-
-
- Selling and Administrative Expenses 32 32
-
-
- Research and Development Expense 123 123
-
-
-158 -158
-
-
- Depreciation and Amortization 3.26 3.26
-
-
EBIT (Operating Income) EBIT -161 -161
-
-
Net Profit -154 -154
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Mural Oncology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mural Oncology Stock News

Neutral
GlobeNewsWire
25 days ago
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options...
Neutral
GlobeNewsWire
about one month ago
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does not typically respond to immunotherapies
Neutral
GlobeNewsWire
about 2 months ago
WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences.
More Mural Oncology News

Company Profile

Mural Oncology Plc operates as a clinical stage company. It focus on discovering and developing immuno therapies that may meaningfully improve the lives of patients with cancer. Its portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The company was founded in May 2017 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Caroline Loew
Employees 117
Founded 2017
Website www.muraloncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today